INBS (INBS) CFO receives time- and performance-based restricted stock grants

Rhea-AI Filing Summary

Sakiris Spiro Kevin reported acquisition or exercise transactions in this Form 4 filing.

INTELLIGENT BIO SOLUTIONS INC. Chief Financial Officer Kevin Sakiris received equity awards in the form of common stock. On March 18, 2026, he was granted 9,150 restricted shares that vest over 48 months and 21,350 restricted shares subject to both performance-based and time-based vesting, all under the 2019 Long Term Incentive Plan.

Following these compensation grants, Sakiris directly holds 33,981 shares of common stock and indirectly holds 1,911 shares through Anest Holdings Pty Ltd, as trustee of the S&T Sakiris Superannuation Fund. All share amounts are presented after a prior 1-for-10 reverse stock split.

Insights

Equity Compensation Analyst

CFO received time- and performance-based stock grants, indicating routine equity compensation rather than market trading.

The transactions show Kevin Sakiris, CFO of INTELLIGENT BIO SOLUTIONS INC., receiving grants of 9,150 and 21,350 restricted common shares at no purchase price, under the 2019 Long Term Incentive Plan. These are non-market awards classified as grant or award acquisitions, not open-market buys.

The 9,150-share award vests purely over 48 months, while the 21,350-share award depends on both performance and time-based conditions, with forfeiture risk until vesting. After these grants, he holds 33,981 shares directly and 1,911 indirectly through Anest Holdings Pty Ltd, giving context to his total reported equity exposure.

All share figures reflect a 1-for-10 reverse stock split completed on December 15, 2025, which adjusted prior holdings and equity awards proportionally. This makes the amounts directly comparable within this filing and avoids confusion with pre-split figures disclosed in earlier periods.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sakiris Spiro Kevin

(Last) (First) (Middle)

C/O INTELLIGENT BIO SOLUTIONS INC.,

135 WEST 41ST STREET, 5TH FLOOR

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INTELLIGENT BIO SOLUTIONS INC. [ INBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/18/2026		A		9,150(2)	A	$0	12,631(1)	D
Common Stock	03/18/2026		A		21,350(3)	A	$0	33,981(1)	D
Common Stock								1,911(1)	I	Held by Anest Holdings Pty Ltd(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On December 15, 2025, Intelligent Bio Solutions Inc. (the "Issuer") effected a 1-for-10 reverse stock split of the Issuer's common stock ("Common Stock"). The reverse stock split effected in December 2025, and prior reverse stock splits effected by the Issuer, resulted in a reduction in the number of shares held by the reporting person and proportional adjustments to the outstanding equity awards held by the reporting person. Accordingly, all amounts in this Form 4 are presented on a post-reverse split basis.

2. On March 18, 2026, the Issuer granted the reporting person 9,150 restricted shares of Common Stock under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan ("2019 Plan"). The awarded shares are subject to time-based vesting after 48 months and are subject to forfeiture until vested.

3. On March 18, 2026, the Issuer granted the reporting person 21,350 restricted shares of Common Stock under the 2019 Plan. The awarded shares are subject to joint performance-based and time-based vesting requirements and are subject to forfeiture until vested.

4. These securities are held by Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, of which Mr. Sakiris is a director.

	/s/ Spiro Sakiris	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did INBS CFO Kevin Sakiris report on March 18, 2026?

He reported two equity grants of common stock. One award was 9,150 restricted shares with 48-month time-based vesting, and another was 21,350 restricted shares with joint performance-based and time-based vesting, both under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan.

How many INBS shares does CFO Kevin Sakiris hold after these Form 4 transactions?

After the reported grants, he directly holds 33,981 shares of Intelligent Bio Solutions Inc. common stock. He also indirectly holds 1,911 shares through Anest Holdings Pty Ltd as trustee of the S&T Sakiris Superannuation Fund, according to the Form 4 disclosures and related footnotes.

Were the INBS shares acquired by CFO Sakiris open-market purchases or equity awards?

They were equity awards, not open-market purchases. Both transactions are coded as grant or award acquisitions, with zero dollar purchase price. The 9,150 and 21,350 shares are restricted stock granted under the company’s 2019 Long Term Incentive Plan, subject to vesting and forfeiture conditions.

What are the vesting terms of the INBS restricted stock granted to CFO Kevin Sakiris?

The 9,150-share award vests solely based on time over 48 months. The 21,350-share award has combined performance-based and time-based vesting requirements. Both grants remain subject to forfeiture until their respective vesting conditions are satisfied, as described in the Form 4 footnotes.

How does the reverse stock split affect the INBS share numbers in this Form 4?

All share amounts are presented on a post-split basis. Intelligent Bio Solutions Inc. completed a 1-for-10 reverse stock split of its common stock on December 15, 2025, which reduced reported holdings and proportionally adjusted outstanding equity awards for the reporting person in this Form 4.

How are the indirectly held INBS shares of CFO Sakiris structured?

The Form 4 shows 1,911 shares held indirectly. These securities are held by Anest Holdings Pty Ltd, as trustee of the S&T Sakiris Superannuation Fund, and Mr. Sakiris is identified as a director of that trustee entity in the filing’s explanatory footnote.